Conectar
To describe and enhance the understanding of healthcare professionals' perceptions of future leadership in digital healthcare.
A qualitative descriptive study.
The data were collected remotely between February and November 2022 through semi-structured interviews. A total of 26 healthcare professionals were interviewed individually or in focus group interviews at the university hospital and university in Finland. The data were analysed using inductive content analysis.
Results revealed seven main categories that described the professionals' perceptions of future leadership in digital healthcare: building a future-oriented healthcare, strengthening a digitally minded organisational culture, being interactive in a digital environment, leading sustainably in digital healthcare, leading expertise in digital healthcare, leading collaboratively in digital healthcare and using artificial intelligence in leadership in digital healthcare.
Future leadership in digital healthcare will be about leading people in a humane way. Leaders will be at the forefront of digital solutions, sharing their expertise and enabling stakeholders' engagement. Through collaboration, future leaders will be building a future-led digital health system.
Digital healthcare is improving due to the implementation of new digital solutions and the possibility of artificial intelligence. Thus, leaders' competencies in digital healthcare need to be further developed through education and guided by policy to meet the expectations of future professionals, nurses and customers.
No patient or public contribution.
The Consolidated Criteria for Reporting Qualitative Research (COREQ) checklist was used in the reporting.
by Thammarat Kaewmanee, Acharaporn Issuriya, Piyapong Choochana, Pinanong Na-Phatthalung, Surasak Limsuwan, Sasitorn Chusri
This study aimed to optimize microencapsulation conditions for Phy-Blica-O (PBO), a traditional Thai polyherbal tonic, and to assess the safety of its consumer-accepted herbal tea formulation, Phy-Blica-D (PBD). PBO decoction and its phenolic-rich extract were spray-dried at different inlet temperatures (140°C, 180°C) and maltodextrin-gum Arabic ratios. Encapsulation efficiency was highest at 140°C with maltodextrin alone, while antioxidant activity was greatest in microcapsules prepared at 180°C with a 6:4 maltodextrin to gum Arabic ratio, as shown by DPPH, ABTS, and FRAP assays. PBD demonstrated strong in vitro antioxidant activities and was subsequently assessed in a 90-day subchronic toxicity study in Wistar rats. No treatment-related mortality, clinical abnormalities, organ toxicity, or hematological or biochemical disruptions were seen at doses up to 300 mg/kg/day, indicating a NOAEL above this level. These findings suggest that optimized PBO microcapsules and the PBD tea blend are safe, antioxidant-rich functional ingredients with strong potential for commercialization in complementary and integrative medicine.Opioid analgesic medications play a critical role in pain management but are associated with significant risks, including addiction. General practitioners in primary care account for a substantial proportion of opioid prescriptions, and prescribing practices may not always fully align with clinical guidelines. Given the limited evidence supporting long-term opioid use for chronic non-cancer pain, there is a pressing need for interventions that promote safer, guideline-concordant prescribing. The Smarta Val (Smart Choices) trial will evaluate whether a new multicomponent intervention, comprising an educational seminar, written materials and feedback on prescribing over 12 months, can improve opioid prescribing practices in primary care.
This cluster randomised pragmatic trial will assess changes in opioid prescribing across primary healthcare centres (PHCCs) in Stockholm, Sweden. Consenting PHCCs will be randomised 1:1 to either the intervention group, receiving the multicomponent intervention, or the active control group, receiving a leaflet on prescribing recommendations. A sample size of 24 PHCCs per group is required to detect differences in opioid prescribing between groups. A third group of non-randomised observational reference PHCCs will be included to provide contextual information on prescribing practices during the study period. Data sources include regional healthcare databases, baseline and 12-month follow-up questionnaires, and an intervention delivery form. The primary outcome is the change in prescription of opioids at 12 months. Secondary outcomes are the change in prescription of opioids at 24 months and the change in the specific opioid substances prescribed at 12 months.
The study has been approved by the Swedish Ethical Review Authority (Dnr 2021-06739-01). Participation in the study requires informed consent from PHCC managers in the intervention and active control groups. Results will be disseminated through international peer-reviewed journals and conference presentations.
To explore implementation patterns and perceived value of the SEXIT (SEXual health Identification Tool) method in the school health care (SHC) setting in Sweden.
Mixed method survey using an online questionnaire with closed and free-text response options.
115 SHC professionals who had completed SEXIT training responded to an online questionnaire (response rate 26%), between March and May 2024. Closed questions were answered on a five-point Likert scale, and responses trichotomised. Quantitative data were analysed using descriptive statistics, qualitative data with a deductive qualitative content analysis. CROSS guideline was used.
70 of 115 SHC professionals used SEXIT in their work. Findings suggest that SEXIT is appropriate and useful, supporting communication about topics such as sexual health and violence that both pupils and professionals may avoid addressing. Implementation patterns showed that 61% of those who had completed training also used SEXIT. 63% of those used SEXIT during regular health dialogues, but some did not use it with all pupils. The perceived value was that most SHC professionals felt that SEXIT helped them get a better understanding of the pupil's situation, an objection that it was too time-consuming.
Most SHC professionals who had completed SEXIT training used the method regularly and perceived the method as valuable and facilitating discussions about sexual ill health and experiences of violence with pupils. There are indications that SHC services fail to identify particularly at-risk young people. Sexual health inequity persists, as some structurally marginalised and vulnerable youths are excluded from the SEXIT dialogues. A follow-up study will focus on pupils' experiences.
This study validates SEXIT in a new setting, SHC, and is relevant for the promotion of sexual and reproductive health for all, and for preventing violence and sexual ill health among young people.
Major depressive disorder (MDD) is a major global healthcare challenge. This is, in part, due to the lack of treatment response and chronic course of MDD. Such a course of illness is often termed treatment-resistant depression (TRD) and is seen in over one-third of people with MDD. Reasons for treatment resistance are not well established, nor is the definition of TRD. Duration and severity of depression, however, are associated with TRD and are also associated with cognitive deficits. Thus, TRD could be particularly prone to cognitive deficits and at heightened risk for neuroprogression. While the cognitive profile of MDD has been investigated in several systematic reviews, no systematic review of cognition in TRD exists to date. The present study will fill this gap in the literature. It is expected that TRD will show more severe cognitive deficits than generally reported in MDD and deficits in all cognitive functions are expected.
A systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines will be performed of the databases Embase, Pubmed/MEDLINE, PsychINFO and Cochrane including peer-reviewed studies on humans using standardised cognitive tests. Pilot searching was performed in January 2025 and the full search will be commenced in June 2025, with additional searches following completion. Where sufficient data are reported, a meta-analysis comparing deficits in TRD with MDD and healthy control participants will be performed; alternatively, effects based on norms will be calculated. Meta-regression, subgroup and sensitivity analyses will be conducted to explore moderators that are sufficiently reported in the literature. The quality of studies will be assessed by the Newcastle-Ottawa Scale.
Ethical approval is not necessary to perform the study, and results will be presented at a suitable conference and published in a peer-reviewed journal.
CRD42024538898.
FreshRSS 